The leadership team of embattled cannabis producer HEXO (NYSE:HEXO,TSX:HEXO) is blaming the lagging pace of store openings in key Canadian provinces for its disappointing quarterly results.

The Quebec-based cannabis company reported a net loss of C$62.4 million in its fiscal Q1 2020 results, released on Monday (December 16). That’s a 10.1 percent rise from the C$56.7 million net loss reported during Q4 2019 and a significant jump from the C$12.8 million net loss in the same period last year.


HEXO’s share price dropped 7.6 percent in New York from market close on Friday (December 13) to the start of the trading session on Monday, when it opened at US$2.08. HEXO experienced a similar drop of 7.8 percent from Friday’s close to Monday’s open in Toronto.

During an earnings call with investors and analysts, HEXO CEO Sebastien St-Louis mentioned that revenue growth continues to be hindered by “slower-than-expected” store openings in key provinces, a now common move by Canadian marijuana executives.

“We don’t believe that the retail channel will be substantially built until the end of 2021 or partway through 2022. The illicit market channel will continue to thrive until retail access is brought to the majority of Canadians,” he said.

Ontario, a key segment of Canada’s marijuana space, has signaled that it’s ready to address its limited number of marijuana retail options.

Last Thursday (December 12), the province issued a statement announcing that it will be getting rid of the cap on cannabis stores in the province and opening up the application process for prospective cannabis retailers in January 2020.

“We have said all along that opening more legal stores is the most effective way to combat the illicit market, protect our kids and keep our communities safe. That is our number one priority,” said Attorney General Doug Downey in a statement.

St-Louis also discussed HEXO’s “aggressive” stance on pricing in an effort to increase its market share with the launch of it value brand, Original Stash, and the toll it’s taken on revenue generation.

“While this has affected our net revenue and our gross margin over the last quarter, we feel that by doing this we’ll be able to significantly reduce the levels of unsold products currently in the supply chain, improve overall sell through and continue to increase our market share across the country,” he said.

To prepare for Cannabis 2.0, the firm is planning on devaluing some of its assets to balance out its inventory needs.

“We’ve taken a hard look at our forecasts, demand-based planning needs and current inventory levels. In light of the changes in demand and downward pressure on the price of dried flower and the wholesale market, we’ve impaired our inventory this quarter by C$25.5 million,” St-Louis told investors. “By addressing these issues now, we’re looking to provide greater transparency to our investors and more accurate financial statements.”

He added that the firm is dedicated to becoming earnings before interest, taxes, depreciation and amortization (EBITDA) positive within the 2020 calendar year. The EBITDA figure has become a leading metric for cannabis companies when indicating benefits to investors.

Stephen Burwash, CFO of HEXO, said that gross margin before fair value adjustments for Q1 2020 came to C$4.6 million, a decrease compared to the C$5.1 million reported in Q4 2019, though he added the company expects higher margins once Cannabis 2.0 products are launched.

Updates on HEXO’s performance and operations

HEXO took a hit after telling investors in November that it had discovered illegal cannabis production at its facility in Niagara, Ontario, in a room that was inadequately licensed.

As part of Monday’s quarterly update, the company confirmed that the total inventory from the unlicensed growing operations was reassessed and has been cleared for sale, rather than facing destruction. The area in question is also now fully licensed.

HEXO has recently been under pressure after a series of missteps for the company, including the retraction of its 2020 guidance; it had initially projected revenue of C$400 million for its 2020 fiscal year.

The firm also announced 200 job cuts in October across its operations, including the resignation of former Chief Manufacturing Officer Arno Groll and former Chief Marketing Officer Nick Davies.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Fundraising, Subscription by Directors and Love Hemp Q1 Trading Update

World High Life Plc (“World High Life” or the “Company”) (AQSE:LIFE) (OTCQB:WRHLF) announces that it has raised £566,206 via the issue of 56,620,600 ordinary shares of 1 pence each in the Company (“Ordinary Shares”; the “Subscription Shares”) at a subscription price of 1.0p per share. The proceeds of the Subscription Shares will be used by the Company for general working capital purposes

Keep reading... Show less

Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) (CSE: LOAN) (FSE: O3X4) (OTCQB: PNNRD) (“Global” or the “Company”) announces it has signed a binding letter of intent (“BLOI”) on January 22, 2021 with EntheoTech Bioscience Inc. (“ET”) a wellness psilocybin leader based in Kelowna, British Columbia and will have the option to earn up to a 19.9% interest in ET.

EntheoTech is a Canadian bioscience company focused on the research and development of products, and protocols to promote brain health, performance optimization, and global wellness, using psychoactive substances such as psilocybin, medicinal mushrooms, and other natural products.

Keep reading... Show less

The new dispensary brings expanded access for patients along Florida’s Atlantic Coast

Trulieve Cannabis Corp. (CSE: TRUL)  (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 78th nationwide. The new 4,600 sq. ft. location marks the Company’s first in the city of Sebastian and second in Indian River county expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less